ID: ALA203300

Max Phase: Preclinical

Molecular Formula: C22H17NO3S2

Molecular Weight: 407.52

Molecule Type: Small molecule

Representations

Canonical SMILES:  Oc1nc2sc3c(c2c(O)c1-c1cccc(Oc2ccccc2)c1)CCCS3

Standard InChI:  InChI=1S/C22H17NO3S2/c24-19-17(13-6-4-9-15(12-13)26-14-7-2-1-3-8-14)20(25)23-21-18(19)16-10-5-11-27-22(16)28-21/h1-4,6-9,12H,5,10-11H2,(H2,23,24,25)

Standard InChI Key:  LLIWZQPZYRXTNO-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 407.52

Molecular Weight (Monoisotopic): 407.0650

AlogP: 6.21

#Rotatable Bonds: 3

Polar Surface Area: 62.58

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 9.44

CX Basic pKa:

CX LogP: 6.31

CX LogD: 6.30

Aromatic Rings: 4

Heavy Atoms: 28

QED Weighted: 0.42

Np Likeness Score: -0.59

References

1. Buchstaller HP, Siebert CD, Steinmetz R, Frank I, Berger ML, Gottschlich R, Leibrock J, Krug M, Steinhilber D, Noe CR..  (2006)  Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor.,  49  (3): [PMID:16451052] [10.1021/jm0503493]

Source

Source(1):

• Scientific Literature